NASDAQ:IDXG Interpace Biosciences 8/2/2024 Earnings Report ProfileEarnings History Interpace Biosciences EPS ResultsActual EPS$0.48Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AInterpace Biosciences Revenue ResultsActual Revenue$12.00 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInterpace Biosciences Announcement DetailsQuarterDate8/2/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Interpace Biosciences Earnings HeadlinesPDI: An Opportunity To Lock In A 14% Yield On CostMay 22, 2025 | seekingalpha.comPDO Vs. PDI: Hold PDO Amid U.S. Credit Rating DowngradeMay 22, 2025 | seekingalpha.comTrump Knows Exactly What He's DoingREVEALED: $194 Trillion Trump Market Pattern Trump fires off a tweet and stocks tank… He gives a speech and the markets soar… Now, a new Trump executive order is set to set off a wave worth a potential $194 trillion in the markets. And Wall Street insider Larry Benedict says it could hand investors who missed out on Trump’s first term a second chance.May 30, 2025 | Brownstone Research (Ad)PDI: A Balanced Way To Get Exposure To Risky Fixed-Income PlaysMay 22, 2025 | seekingalpha.comPDI: Don't Buy This 14% YieldMay 21, 2025 | seekingalpha.comInterpace Biosciences Announces First Quarter 2025 Financial and Business ResultsMay 9, 2025 | finance.yahoo.comSee More Interpace Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Interpace Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Interpace Biosciences and other key companies, straight to your email. Email Address About Interpace BiosciencesInterpace Biosciences (NASDAQ:IDXG) provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.View Interpace Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles CrowdStrike Stock Slips: Analyst Downgrades Before Earnings Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAdvance Auto Parts: Did Earnings Defuse Tariff Concerns?Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Upcoming Earnings CrowdStrike (6/3/2025)Haleon (6/4/2025)Broadcom (6/5/2025)Oracle (6/10/2025)Adobe (6/12/2025)Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.